A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612

Leuk Lymphoma. 2023 Feb;64(2):473-477. doi: 10.1080/10428194.2022.2148212. Epub 2022 Dec 14.

¹ McGill University - Jewish General Hospital, Montreal, Canada.
² Medical College of Wisconsin, Milwaukee, WI, USA.
³ SWOG Statistics and Data Management Center, Seattle, WA, USA.
⁴ Queen's University, Kingston, Canada.
⁵ Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
⁶ Washington University School of Medicine, St. Louis, MO, USA.
⁷ Kaiser Permanente NCAL, Roseville, CA, USA.
⁸ Kaiser Permanente, Santa Clara, CA, USA.
⁹ Moffitt Cancer Center, Tampa, FL, USA.
¹⁰ University of Oklahoma HSC, Oklahoma City, OK, USA.
¹¹ Illinois CancerCare/Heartland NCORP, Peoria, IL, USA.
¹² SWOG Data Operations Center/Cancer Research and Biostatistics, Seattle, WA, USA.
¹³ Cancer Therapy and Evaluation Program (CTEP), National Cancer Institute, Bethesda, MD, USA.
¹⁴ Duke University Medical Center, Duke Cancer Institute, Durham, NC, USA.

No abstract available

Publication types